Access Financial Services Inc. increased its stake in Pfizer, Inc. (NYSE:PFE) by 16.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,587 shares of the biopharmaceutical company’s stock after buying an additional 5,477 shares during the period. Pfizer comprises about 1.1% of Access Financial Services Inc.’s portfolio, making the stock its 28th largest position. Access Financial Services Inc.’s holdings in Pfizer were worth $1,296,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of PFE. Associated Banc Corp increased its stake in Pfizer by 5.0% in the fourth quarter. Associated Banc Corp now owns 803,992 shares of the biopharmaceutical company’s stock valued at $26,114,000 after buying an additional 38,201 shares during the last quarter. McAdam LLC bought a new stake in Pfizer during the fourth quarter valued at approximately $289,000. United Bank bought a new stake in Pfizer during the fourth quarter valued at approximately $2,137,000. Aspiriant LLC increased its stake in Pfizer by 5.3% in the fourth quarter. Aspiriant LLC now owns 38,316 shares of the biopharmaceutical company’s stock valued at $1,245,000 after buying an additional 1,937 shares during the last quarter. Finally, Glenview Trust Co bought a new stake in Pfizer during the fourth quarter valued at approximately $6,241,000. Institutional investors and hedge funds own 69.95% of the company’s stock.
Shares of Pfizer, Inc. (PFE) opened at 33.43 on Monday. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $37.39. The stock has a market cap of $199.51 billion, a PE ratio of 28.14 and a beta of 1.01. The stock’s 50 day moving average is $32.80 and its 200-day moving average is $33.17.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.67 by $0.02. The business had revenue of $12.78 billion during the quarter, compared to the consensus estimate of $13.09 billion. Pfizer had a net margin of 13.76% and a return on equity of 23.68%. The business’s revenue was down 1.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.67 EPS. On average, analysts predict that Pfizer, Inc. will post $2.55 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.83%. Pfizer’s dividend payout ratio is presently 108.48%.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://transcriptdaily.com/2017/07/17/access-financial-services-inc-increases-stake-in-pfizer-inc-nysepfe.html.
PFE has been the subject of several research reports. BMO Capital Markets reiterated a “hold” rating and set a $33.00 price objective on shares of Pfizer in a research note on Tuesday, March 21st. Societe Generale reissued a “neutral” rating and set a $36.00 target price on shares of Pfizer in a report on Thursday, March 23rd. Sanford C. Bernstein reissued a “buy” rating and set a $35.00 target price on shares of Pfizer in a report on Friday, March 24th. Morgan Stanley reissued a “neutral” rating and set a $38.00 target price on shares of Pfizer in a report on Thursday, April 6th. Finally, Jefferies Group LLC reissued a “neutral” rating and set a $35.00 target price (up previously from $34.00) on shares of Pfizer in a report on Thursday, April 13th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $37.68.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.